Glioblastoma has remained one of the toughest cancers to treat, resisting even the latest advances in immunotherapy. But new ...

Glioblastoma has long resisted treatment, but scientists may have found a breakthrough by leveraging the body's own ...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...

Glioblastoma has remained one of the toughest cancers to treat, resisting even the latest advances in immunotherapy.

While PD-1/PD-L1 blockade has demonstrated remarkable clinical successes, recent studies suggest that its novel target has a ...

Karnataka: Shilpa Biologicals Pvt Ltd., a fully owned subsidiary of Shilpa Medicare Limited has signed an exclusive ...

AbTree Biologics AG has signed an exclusive co-development and commercialization partnership with Shilpa Biologicals Pvt Ltd.

Oncolytic viruses, once considered medical curiosities, are now cutting-edge tools in the fight against some of the most ...

Scratching your skin can feel satisfying, but learn how it impacts inflammation and bacterial infection defense.

The therapy, a fully human monoclonal antibody, targets a newly identified immune checkpoint protein that could enhance ...

The novel therapy is anticipated to function like PD-1/PD-L1 blockade with significant clinical efficacy results in ...